¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Assay and drug development technologies."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý (ÇÐ)(ËÎËÛ ËâËôË×̰).
  • maximum and minimum thermometer
    ÃÖ°í ÃÖÀú¿Âµµ°è(õÌÍÔõÌî¸è®öôͪ).
  • maximum and minimum thermometer
    ÃÖ°í ÃÖÀú¿Âµµ°è(Ì§Ë­Ì§ËøËí̬˭).
  • medial and inferior surface
    ¾ÈÂÊ¸é ¹× ¾Æ·¡¸é
  • mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
  • mitral stenosis and insufficiency
    ½Â¸ðÆÇÇùÂø ¹× Æó¼âºÎÀüÁõ(¡­øÍáðÝÕîïñø).
  • mitral stenosis and insufficiency
    ½Â¸ðÆÇÇùÂø ¹× Æó¼âºÎÀüÁõ(¡­øÍáðÝÕîïñø)
  • mixed anxiety and depression
    È¥À缺 ºÒ¾È¿ì¿ïº´(ûèî¤àõ ÝÕäÌéØê¦Ü»)
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾(¡­ ÓÞá³á¬øà ¡­ðþ)
  • mode and course of progress
    ÁøÇà¾ç½Ä ¹× °úÁ¤
  • mouth and hand synkinesis
    ±¸¼ö°øµ¿¿îµ¿(Ï¢â¢ÍìÔÒê¡ÔÑ).
  • muscle of upper lip and ala of nose, levator =mus
    »ó¼øºñÀͰűÙ
  • muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
  • myoclonic epilepsy and raggedred fibers
    °£´ë±ÙÀ°°æ·Ã¼º°£Áú(ÊàÓÛÐÉë¿ÌâÕýàõÊÖòð)
  • normal temperature and pressure
    »ó¿ÂÁ¤»ó±â¾Ð(Ë×ËíËøË×Ë»Ëâ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
TED Tasks of Emotional Development; threshold erythema dose; thromboembolic disease
ADAMHA Alcohol, Drug Abuse, and Mental Health Administration
ADDU alcohol and drug dependence unit
ADME [drug] absorption, distribution, metabolism, and excretion
AL absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
IVDA intravenous drug abuser
IVDA Intravenous drug addicts
IVDU Intravenous drug use
IDU Intravenous drug users
IND Investigational New Drug
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • individual drug
    °³°³ÀÎ ¾à¹°
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ¾àǰ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • narcotic drug
    ¸¶¾à
    ¸ð¸£ÇÉ, ÄÚÄ«ÀÎ, ¾ÆÆí µî°ú ±× À¯µµÃ¼·Î¼­ ¹Ì·®À¸·Î °­·ÂÇÑ ÁøÅë ÀÛ¿ë°ú ¸¶Ãë ÀÛ¿ëÀ» Áö´Ï¸ç °è¼Ó »ç¿ëÇÏ¸é ½À°ü¼º°ú Ž´Ð¼ºÀÌ »ý±â°Ô ÇÏ´Â ¹°Áú. »ç¿ëÀ» Áß´ÜÇÏ¸é °Ý·ÄÇÑ ±Ý´Ü Áõ¼¼¸¦ ÀÏÀ¸ÄÑ ¸¶¾àÀ» »ç¿ëÇÏÁö ¾Ê°í´Â Á¤»óÀûÀÎ »ýȰÀ» ÇÒ ¼ö ¾ø°Ô µÇ¸ç, Á¾±¹¿¡ °¡¼­´Â À°Ã¼ÀûÀ¸·Î³ª Á¤½ÅÀûÀ¸·Î ÆóÀÎÀÌ µÇ°Ô ÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ·± ¹°ÁúÀÌ ÀÇ·á ¹× ¿¬±¸ ÀÌ¿ÜÀÇ ¸ñÀû¿¡ ³²¿ëµÇ´Â À§ÇèÀ» ¹æÁöÇϱâ À§ÇÏ¿© Á¤ÇÑ ¹ý·ü»ó ¿ë¾î°¡ ¸¶¾àÀÌ´Ù. ¸¶¾àÀº ¨ç ¾Þ¼Ó¿¡¼­ äÃëÇÏ´Â ¾ÆÆí ¾ËÄ®·ÎÀ̵å°è ¸¶¾à
  • negative drug history
    À½¼º Åõ¾à º´·Â
  • neuroleptic drug
    ½Å°æ ÀÌ¿ÏÁ¦
  • new drug application
    ½Å¾à Çã°¡ ½Åû
  • non-respiratory depressant drug
    ºñ-È£Èí ¾ïÁ¦Á¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
instillation, drug The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from irrigation in that the irrigate is removed within minutes, but the instillate is left in place.
(12 Dec 1998)
investigational new drug Status given an experimental drug after the FDA approves an application for testing it in people.
(09 Oct 1997)
investigational new drug application An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured.
(12 Dec 1998)
orphan drug A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential.
(09 Oct 1997)
orphan drug act Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug.
(14 Nov 1997)
orphan drug production Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.
(12 Dec 1998)
targeted drug delivery Delivering a drug to a specific site in the body where it has the greatest effect, instead of allowing it to diffuse to various sites, where it may cause damage or trigger side effects.
(14 Nov 1997)
fixed drug eruption A type of drug eruption that recurs at a fixed site (or sites) following the administration of a particular drug; the lesions usually consist of intensely erythematous and purplish, sharply demarcated macules, and occasionally of herpetic vesicles; the affected areas undergo gradual involution, but flare and enlarge on readministration of the offending drug and may become hyperpigmented.
Iodine eruption, an acneform or follicular eruption or granulomatous lesion caused by a reaction to systemic iodine or iodide administration.
Kaposi's varicelliform eruption, a now rare complication of vaccinia superimposed on atopic dermatitis, with generalised vesicles and vesicopapules and high fever.
Synonym: eczema vaccinatum.
(05 Mar 2000)
food-drug interactions The pharmacological result, either desirable or undesirable, of drugs interacting with components of the diet.
(12 Dec 1998)
legislation, drug Laws concerned with manufacturing, dispensing, and marketing of drugs.
(12 Dec 1998)
abstracting and indexing Shortening or summarizing of documents; assigning of descriptors for referencing documents.
(12 Dec 1998)
academies and institutes Organizations representing specialised fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., national academy of sciences, brookings institution, etc.
(12 Dec 1998)
accounts payable and receivable Short-term debt obligations and assets occurring in the regular course of operational transactions.
(12 Dec 1998)
aged, 80 and over A person 80 years of age and older.
(12 Dec 1998)
algae and fungi Algae represent a group of spore-propagating plants, unicellular or undifferentiated into root, stem, and leaf. They include seaweed and many unicellular fresh water plants, most of which contain chlorophyll. They account for about 90% of the earth's photosynthetic activity. Fungi are eukaryotic, heterotrophic organisms that live as saprobes or parasites and include mushrooms, yeasts, smuts, molds, etc. They lack chlorophyll.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á